Kevin R. Lind
2023 - Longboard Pharmaceuticals
In 2023, Kevin R. Lind earned a total compensation of $2.1M as President and Chief Executive Officer at Longboard Pharmaceuticals, a 36% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $442,860 |
|---|---|
| Option Awards | $986,934 |
| Salary | $610,000 |
| Other | $14,010 |
| Total | $2,053,804 |
Lind received $986.9K in option awards, accounting for 48% of the total pay in 2023.
Lind also received $442.9K in non-equity incentive plan, $610K in salary and $14K in other compensation.
Rankings
In 2023, Kevin R. Lind's compensation ranked 508th out of 2,990 executives tracked by ExecPay. In other words, Lind earned more than 83.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 508 out of 2,990 | 83rd |
Division Manufacturing | 291 out of 1,640 | 82nd |
Major group Chemicals And Allied Products | 201 out of 909 | 78th |
Industry group Drugs | 198 out of 872 | 77th |
Industry Pharmaceutical Preparations | 125 out of 630 | 80th |
Source: SEC filing on April 12, 2024.
Lind's colleagues
We found two more compensation records of executives who worked with Kevin R. Lind at Longboard Pharmaceuticals in 2023.